Multiparametric flow cytometry has proven to be a powerful method for detection and immunophenotypic characterization of clonal subsets, particularly in lymphoproliferative disorders of the B-cell lineage. Although in theory promising, this approach has not been comparably fulfilled in mature T-cell malignancies. Specifically, the T-cell receptor-Vb repertoire analysis in blood can provide strong evidence of clonality, particularly when a single expanded V family is detected. The purpose of this study was to determine the relevance of this approach when applied to biopsies, at the site of tumor involvement. To this end, 30 peripheral T-cell lymphoma and 94 control biopsies were prospectively studied. Vb expansions were commonly detected within CD4 þ or CD8 þ T cells (97% of peripheral T-cell lymphoma and 54% of non-peripheral T-cell lymphoma cases); thus, not differentiating malignant from reactive processes. Interestingly, we demonstrated that using a standardized evaluation, the detection of a high Vb expansion was closely associated with diagnosis of peripheral T-cell lymphoma, with remarkable specificity (98%) and sensitivity (90%). This approach also identified eight cases of peripheral T-cell lymphoma that were not detectable by other forms of immunophenotyping. Moreover, focusing Vb expression analysis to T-cell subsets with aberrant immunophenotypes, we demonstrated that the T-cell clone might be heterogeneous with regard to surface CD7 or CD10 expression (4/11 cases), providing indication on 'phenotypic plasticity'. Finally, among the wide variety of Vb families, the occurrence of a Vb17 expansion in five cases was striking. To our knowledge, this is the first report demonstrating the power of T-cell receptor-Vb repertoire analysis by flow cytometry in biopsies as a basis for peripheral T-cell lymphoma diagnosis and precise T-cell clone identification and characterization.
Peripheral T-cell lymphomas are hematological malignancies that are thought to develop from transformed lymphocytes of post-thymic origin. These disorders account for about 10% of all nonHodgkin's lymphomas in Western countries.
1,2 Their diagnosis relies on clinical, morphological and immunohistochemical evaluation. However, since none of these criteria are disease-specific, peripheral T-cell lymphoma diagnosis remains challenging, as evidenced by a large multicentric study where misclassification occurred in 10.4% of peripheral T-cell lymphoma cases. 3 Therefore, complementary methods such as the assessment of T-cell clonality are generally required. Molecular techniques aiming at identifying monoclonal rearrangements of the gene loci of the T-cell receptor (TCR)g or chains are the gold standard, [4] [5] [6] revealing the presence of a T-cell clone in 60-100% of peripheral T-cell lymphomas [7] [8] [9] [10] with good specificity, albeit not 100%. 10 Although very useful in routine diagnosis, molecular assays are not quantitative, and do not allow the immunological characterization of the T-cell clone, which is a requisite for improving our knowledge of the malignant T cells involved in peripheral T-cell lymphomas.
In this setting, TCR repertoire analysis by flow cytometry offers significant opportunities, since it allows assessment of T-cell clonality, as well as immunophenotyping of malignant cells and quantification of tumor burden. 11 Current immunophenotyping panels include a total of 25 monoclonal antibodies directed against epitopes of the variable region of the TCR-chain (V), covering about 70% of the T-cell repertoire according to the manufacturer. This technique has proved useful in detecting malignant T cells in peripheral blood samples from patients with diverse mature T-cell leukemias. [11] [12] [13] [14] [15] [16] T-cell clones use the same V domain, and are thus detected by an overexpressed V family (direct identification) or by a restricted V repertoire if they are not recognized by the 25 anti-V antibodies of the panel (indirect identification). However, T-cell clone analysis in blood samples is not optimal for peripheral T-cell lymphomas, as (1) there may be no circulating lymphoma cells, (2) malignant circulating cells may not precisely reflect the clone at the site of tumor involvement and (3) when present, clonal subsets are not always malignant, as observed in infectious or autoimmune conditions, as well as in elderly people. [17] [18] [19] [20] It should be noted that the applicability of the TCR-V repertoire analysis in various biopsy samples has already been reported by several groups including ours. 21 What remains unknown is the capacity of this approach to detect malignant T cells in peripheral organs and its power to differentiate malignant from reactive V expansions, which are expected to be frequent at the site of immune reactions. To answer this question, we prospectively examined a total of 30 biopsies involved by peripheral T-cell lymphomas and 94 lymphoid tissues not involved by T-cell lymphomas as control biopsies.
Immunophenotyping is part of the routine diagnosis of lymphomas as recommended by the 2008 WHO classification, 22 and is commonly performed using immunohistochemical techniques. Pan-T-cellassociated antigens such as CD2, CD3, CD7 and CD5 are important in confirming the T-cell origin of a suspect population. Demonstration of the loss of one or more of these antigens can also be used as a surrogate marker for T-cell clonality, as opposed to the complete phenotype of normal T-lymphocytes. It is worth noting that it is neither constant nor completely tumor-specific. [23] [24] [25] [26] As their normal counterparts, T-cell clones belong to one of the CD4 þ , CD8 þ and more rarely CD4ÀCD8À or CD4 þ CD8 þ subsets. However, this may be difficult to determine, especially in the case of minor tumor involvement. As flow cytometry has proven to be efficient in peripheral T-cell lymphoma immunophenotyping, we aimed at determining the relevance of TCR-V repertoire analysis for the characterization of the T-cell clone.
Materials and methods

Patients and Biopsy Samples
We conducted a prospective study from November 2000 to August 2010 at Grenoble University Hospital. Patients provided informed consent, according to the protocol approved by the Institutional Review Board. Surgical biopsies were obtained from patients with suspicion of lymphoma. A single biopsy was used for morphological, flow cytometry, cytogenetic and molecular studies, according to the standard institutional protocol. 21 A total of 124 biopsies fulfilling the following criteria were included: (i) at least 5 million cells recoverable for analysis, (ii) more than 80% viable cells, (iii) expression of the TCRab/CD3 complex on T-cell membrane and (iv) more than 25% CD3 þ cells in the whole population. The biopsy sites were lymph nodes (n ¼ 118), tonsil (n ¼ 2), orbit (n ¼ 1), spleen (n ¼ 2) or skin (n ¼ 1). Biopsies were collected from 124 patients aged 7-87 years (median 51). The male to female ratio was 1.61:1.
Histopathology
In all, 30 biopsies from 30 patients were diagnosed as peripheral T-cell lymphomas using histology and immunohistochemical evaluation according to the 2008 WHO classification of hematological malignancies. 22 They consisted of 13 peripheral T-cell lymphomas not otherwise specified, 14 angioimmunoblastic T-cell lymphomas, 1 Sezary syndrome, 1 adult T-cell leukemia/lymphoma and 1 T-cell prolymphocytic leukemia. The 94 remaining biopsies were controls. They were defined as lymphoid tissues not infiltrated with peripheral T-cell lymphomas, that is, with non-malignant resident T cells. They comprised 37 reactive hyperplasias, 27 Hodgkin's lymphomas, 23 B-cell lymphomas, 6 adenocarcinomas and 1 Castleman disease. In total, 81 cases had been reported previously. 21 Immunophenotyping and TCR-Vb Repertoire Analysis by Flow Cytometry Biopsies were processed during the first 48 h after surgical excision as described previously. 21 Four-color immunostaining was performed using TCR-Vb repertoire analysis by flow cytometry in PTCL biopsies D Salameire et al standard techniques, and analyses were conducted with a FACScalibur and CellQuest-Pro software (BD Biosciences, San Jose, CA, USA). The panel of monoclonal antibodies routinely used to detect and classify T-lymphoid malignancies was as follows: PE-Cy5-CD3 (UCHT1), FITC-CD4 (13B8.2), PE-CD8 (B9.11) and PE-CD10 (ALB1) from Beckman Coulter (Brea, CA, USA), and PE-CD7 (M-T701), FITC-CD2 (RPA-2.10) and FITC-CD5 (UCHT2) from BD Biosciences. This panel allows appreciation of the proportion of T-cell subsets in the biopsies and detection of immunophenotypic abnormalities, that is, loss of a pan-T-cell antigen (considered aberrant when the proportion of negative T cells exceeded 3% of total lymphocytes for CD3, or 15% for CD2, CD5 or CD7), or CD10 expression (considered abnormal when positive T-cell accounted for more than 5% of total lymphocytes). These criteria were based on our experience in phenotyping control biopsies. Such characteristics were further used to focus the TCR-Vb repertoire analysis on a particular T-cell subset.
The TCR-Vb repertoire was analyzed using 25 monoclonal antibodies directed against the variable (V) region of the TCR-chain, including 24 V families from the IOTest Beta Mark kit (Beckman Coulter) and V6.7 (Endogen, Woburn, MA, USA), as reported previously. 21 PE-Cy7-CD4 (SFCI2TD11) and APC-CD8 (B9.11) from Beckman Coulter were combined with Vb monoclonal antibodies to study the TCR repertoire of the so defined T-cell subsets in a single experiment. For peripheral T-cell lymphomas, other gating monoclonal antibodies were used, according to the particular T-cell clone phenotype: PE-Cy7-CD4 and APC-CD7 (CD7.6B7; CliniScience, Montrouge, France) when a defect in CD7 expression was demonstrated (n ¼ 8), PE-Cy7-CD4 and APC-CD10 (H10a, BD Biosciences) when CD10 was positive on T cells (n ¼ 1) and PE-Cy7-CD3 (UCHT1, Beckman Coulter) when the T-cell clone expressed neither CD4 nor CD8 (n ¼ 2).
On the basis of our previous work assessing reference values for V families in CD4 þ and CD8 þ T-cell populations in lymph nodes, 21 T-cell expansions were defined as follows: (i) V percentage over the mean þ 3 s.d. reference value within the corresponding T-cell subset (ie, CD4 þ or CD8 þ ), or (ii) sum of all 25 V percentages below the mean À 3 s.d. reference value in the corresponding T-cell subset (ie, 54% in CD4 þ and 41% in CD8 þ T cells). In the latter cases, expansions were not recognized directly by the monoclonal antibodies from the panel and were therefore referred to as 'out of panel' V expansions. For Vb expansions assessed within the 'double-negative' CD3 þ CD4ÀCD8À T-cell subset, the same reference values as for CD4 þ T cells were used. In an effort to standardize the level of Vb expansion, we calculated a ratio (Vb ratio) between the observed V percentage and the upper reference value (ie, mean þ 3 s.d.) of the corresponding family.
Cytogenetic and Molecular Cytogenetic Analyses
Cytogenetic analysis was performed on the same cell suspensions as were used for flow cytometry analysis, following 17 h unstimulated culture and a colchicine block. R-banded metaphase chromosomes were prepared by standard procedures. 27 
Multiplex PCR Amplification and PCR Product Analysis
Genomic DNA was isolated from frozen tissue biopsies using standard procedures. 27 Detection of clonal TCRg gene rearrangements was performed using two techniques: (1) genomic DNA was submitted to a single multiplex polymerase chain reaction (PCR) using GC-clamp primers and analyzed by denaturing gradient gel electrophoresis, as described by Theodorou et al. 4 (2) Samples were submitted to TCRg gene rearrangement amplification followed by Genescan analysis as described previously. 28 
Results
In all, 30 patients with peripheral T-cell lymphomas were prospectively included in this study. The details of clinical, histological, immunological, cytogenetic and molecular analyses are summarized in Table 1 .
Vß Expansions are Observed in Both Peripheral T-Cell Lymphomas and Control Biopsies
Vb expansions were assessed within the CD4 þ and CD8 þ T-cell subsets, except for double-negative peripheral T-cell lymphoma cases for which they were evaluated within CD3 þ cells. An expansion of at least one Vb family was directly recognized by one of the 25 monoclonal antibodies from the panel in 29/30 peripheral T-cell lymphomas (97%) and 51/94 control cases (54%). Additional Vb expansions were indirectly identified in peripheral T-cell lymphoma cases only (5/30, 17%) (Supplementary Data 1). Of note, V expansion within CD4 þ T cells was unique in 20/27 peripheral T-cell lymphomas (74%) vs 18/94 control cases (19%). In contrast, 8/21 peripheral T-cell lymphomas (38%) and 23/94 control cases (24%) displayed this characteristic within CD8 þ T cells. The expansion was unique in all three double-negative cases. When multiple in biopsies, Vb expansions ranged from 2 to 6 within the CD4 þ subset, and from 2 to 5 within CD8 þ T cells.
Because of their high frequency in control biopsies, the presence of a Vb expansion, whether single or multiple, was thus not sufficient to distinguish T-cell lymphomas from non T-cell lymphoma lesions. expansions of individual Vb families, we used a normalized ratio (Vb ratio) calculated between the observed Vb percentage and the upper reference value of the corresponding family. 21 As shown in Table 2 , Vb ratio ranged from 1 to 21 within CD4 þ T cells, and from 1.1 to 6.5 within CD8 þ T cells. We graphically considered that a Vb ratio cutoff value of three best separated patients with either high or low Vb expansions (Figure 1b) . Using this criterion, 23 cases displayed a high Vb expansion within the CD4 þ or the double-negative T-cell subsets. Of these, 22 cases (96%) were peripheral T-cell lymphomas (mean Vb ratio: 8.7; range: 3.1-21) and one case (4%) was not (mean Vb ratio: 3). The expansion was unique in all cases (Figure 1b) . In the CD8 þ subsets, all Vb expansions presented a Vb ratio lower than 3, except in three control cases (3/94, 3%). The expansion was unique in only one of them, a case of Hodgkin's lymphoma (patient 32, Vb ratio: 6.5). For all cases with high Vb expansions, the proportion of the expanded V family in total lymphocytes ranged from 4 to 82.8% (mean: 35.8%).
Thus, a high and unique, 'in' or 'out of panel' Vb expansion was observed in 27/30 peripheral T-cell lymphomas (90%), exclusively within CD4 þ or double-negative T cells. In control biopsies, this occurred in only 2/94 cases (2%), within CD4 þ as well as CD8 þ T cells.
The three peripheral T-cell lymphoma cases with no or low Vb expansions (patients 28-30) had been classified as peripheral T-cell lymphomas not otherwise specified (patient 30) or angioimmunoblastic T-cell lymphoma (patients 28 and 29) . None demonstrated an aberrant immunophenotype (Table 1) . Clonal TCRg rearrangements were detected in patient 28, by both denaturating gradient gel electrophoresis and Genescan analyses, whereas a faint clonal rearrangement in a polyclonal background was identified only by Genescan in patient 29. In this latter case, a pseudotetraploid (91-95 chromosomes) 'chaotic' karyotype was observed (8/21 mitoses) and DNA content assessed by flow cytometry was near tetraploid in 5% of the cells (data not shown). In contrast, patient 30 did not show any clonal aberration either by flow cytometry, cytogenetic or molecular assays (Supplementary Data 2) .
Quite strikingly, both control biopsies presenting a high and unique Vb expansion within one of the CD4 þ or CD8 þ T-cell subsets were found to display clonal TCRg rearrangements using molecular techniques, thereby confirming the presence of a T-cell clone. Patient 31 was diagnosed with reactive hyperplasia in the context of EBV infection, confirmed by the detection of IgM EBNA antibodies and EBV PCR products. Patient 32 was diagnosed with T-lymphocyte-rich Hodgkin's lymphoma of the orbit. Loss of CD7 expression was observed on CD8 þ T cells. It is worth noting that karyotypic abnormalities were detected in both cases, albeit of nonspecific nature (Supplementary Data 2) .
In summary, using a Vb ratio threshold value of 3, TCR-V repertoire analysis showed a sensitivity of 90% and a specificity of 98% for the diagnosis of peripheral T-cell lymphomas, and the T-cell clone could be identified as a specific V expansion in 73% (22/30) of cases ( Figure 1 ).
T-cell Clones can be Heterogeneous with Respect to T-Cell Antigens or CD10 Expression
As shown in Table 1 , 19/30 peripheral T-cell lymphoma cases (63%) exhibited aberrant cell surface molecule expression patterns by flow cytometry. CD7 expression was absent in 19/30 (63%) of cases and CD10 was present in 8/30 (27%). In addition, three TCRab-expressing cases demonstrated neither CD4 nor CD8 positivity.
Of note, V expansions were not only detected, directly or indirectly, in all peripheral T-cell lymphoma cases with phenotypic aberrations, but also in eight cases with normal expression of lymphocyte markers.
Interestingly, in 11 lymph node biopsies (Table 3) , we could focus TCR-V repertoire analysis on particular T-cell subsets using specific gating antibodies: (i) CD4 and CD7 for eight cases in which the CD4 þ lymphoma cells demonstrated a defect in CD7 expression; (ii) CD3 and CD7 for two CD4 and CD8 double-negative cases also presenting a CD7À phenotype; or (iii) CD4 and CD10 for one case positive for CD10. As expected, the expanded V family was selectively increased in the T-cell population presenting an aberrant phenotype compared with the whole CD4 þ or CD3 þ subsets. In four cases, the expanded V family was also overrepresented in T lymphocytes expressing a 'normal' phenotype, whereas in seven cases, its expression was within normal ranges ( Figure 2) .
A Large Set of Vß Families are Expressed in Peripheral T-Cell Lymphomas
The T-cell clone was identified by one of the 25 monoclonal antibodies from the panel in 22/30 cases of peripheral T-cell lymphomas (73%) ( Table 2 ). A total of 14 different Vb families were involved, most of them in one case or two cases each. Only V3 and Vb17 were more frequently expressed, that is, in three and five cases, respectively. In the remaining five peripheral T-cell lymphoma cases (17%), the T-cell clone could not be recognized by the monoclonal antibodies of the panel (Figure 3 ).
Discussion
In this prospective study on a large cohort of 124 patients (30 peripheral T-cell lymphomas, 94 control cases), we demonstrated for the first time that TCR-Vb repertoire analysis by flow cytometry represents a sensitive and specific tool to detect, identify and quantify malignant T-cell clones in lymphoid tissue biopsies. We chose to investigate biopsies rather than blood samples since peripheral T-cell lymphoma cases exist with no leukemic involvement. Furthermore, analysis in biopsies is more adapted to unambiguous identification of the malignant T-cell clone since, as mentioned previously, clonal circulating T cells are frequently observed in non-malignant conditions, leading to potential confusion between reactive and tumor cells. 17 On the basis of the promising results obtained from blood samples, [11] [12] [13] [14] [15] [16] we used flow cytometry to assess the expression of 25 Vb chain members of the TCR. Indeed, T-cell clones use a single Vb domain and can thus be identified by the abnormal expansion of one Vb family or by a restricted TCR-Vb repertoire (see Materials and methods). Using our previously reported criteria for defining Vb expansions, 21 clonal subsets were thus found in 97% of peripheral T-cell lymphomas and 54% of control cases, and thus suggesting that this parameter is not suitable for distinguishing malignant and reactive processes, [29] [30] [31] despite significant statistical differences. In contrast, we demonstrated that assessment of the magnitude of Vb expansion by the calculation of a Vb ratio is highly discriminative. 21 Using a threshold value of 3, the presence of a high Vb expansion was found to be closely associated with a OP: out of panel. Figure 2 Simultaneous analysis of aberrant T-cell immunophenotype and V expansion. Lymphocytes from patient 9 (a) and 4 (b) lymph nodes were stained with the anti-V combination of the IOTest Beta Mark kit containing the previously identified expanded family (FITC-PE-V5.1 for patient 9 and FITC-PE-V17 for patient 4), in combination with PECy7-CD4 and APC-CD7 antibodies. CD4 þ CD7 þ and CD4 þ CD7À T cells were gated separately (a and b, left), and the frequency of the expanded Vb family was reported within each subset (a and b, right). In patient 9, the expanded Vb family was mainly CD7À, whereas for patient 4, it consisted of both CD7À and CD7 þ cells. [17] [18] [19] [20] The high specificity of the present approach with respect to peripheral T-cell lymphoma diagnosis might result from its application to biopsy samples rather than to peripheral blood, and from its ability to precisely measure the size of the clone, 11 which appears as an advantage over semiquantitative molecular methods. In the B-cell lineage, quantification of the clone is also a relevant parameter to distinguish some B-cell-derived disorders as myeloma or chronic lymphoid leukemia from non-malignant expansions, respectively, monoclonal gammopathy of undetermined significance and monoclonal B lymphocytosis. 22 False-negative cases with no Vb expansion despite the histological diagnosis of peripheral T-cell lymphoma were rare in our series (3/30) . Two cases (patients 28 and 29) undoubtedly reflected technical limitations in the flow cytometry analysis as T-cell clones were detected by other techniques. In the third case (patient 30), clonality was not demonstrated in several biopsies whatever the technique used (TCR gene rearrangement, flow cytometry and karyotype). Whether this indicated the presence of a very minor clone or represented a false positive of histology could not be definitively judged by this analysis alone. This is in line with molecular reports of peripheral T-cell lymphoma cases without the identification of a T-cell clone, despite the use of sensitive methods. 6 Because of the criteria employed with regard to the magnitude of Vb expansions, TCRVb repertoire analysis by flow cytometry might only be able to detect large malignant populations, depending on the expanded Vb family (three times the upper reference value of the Vb family). 21 Nevertheless, our results demonstrated that this limitation only marginally impacts on peripheral T-cell lymphoma diagnosis, as only 3/30 peripheral T-cell lymphoma cases were not detected in our series. The sensitivity of TCR-Vb repertoire analysis appears similar to what can be expected from molecular assays according to published studies, 6, 32 although this comparison implies data derived from different cohorts of patients.
Another approach for T-cell clonality relies on the detection of an aberrant immunophenotype, that is, absence of expression of a T-cell marker-CD2, CD3, CD5, CD7-or positivity for CD10 (75% of peripheral T-cell lymphomas in our institution (data not shown), in accordance with the literature). 23 In the present series of 30 peripheral T-cell lymphomas, CD3À clones have been excluded because of the associated absence of TCR. They account for 35% of all peripheral T-cell lymphomas using flow cytometry analysis. Interestingly, we showed that high Vb expansions were always associated with phenotypic abnormalities in biopsies, arguing that this criterion is very specific for the diagnosis of peripheral T-cell lymphomas. Furthermore, high Vb expansions were also observed in eight biopsies without detectable membrane marker expression loss or CD10 expression, indicating that the TCR-Vb analysis increased the sensitivity of immunophenotypic diagnosis of peripheral T-cell lymphomas with expression of the CD3/TCRab complex at the membrane. Hence, it is postulated that TCR-Vb repertoire analysis by flow cytometry could be regarded as a promising approach in the peripheral T-cell lymphoma diagnosis strategy. Importantly, the demonstration that malignant T-cell clones could be unambiguously identified by one of the 25 anti-Vb monoclonal antibodies in 73% of peripheral T-cell lymphomas provides a powerful marker for more precise characterization of the tumour clone without confusion with reactive T cells. Such an approach proved to be very informative to phenotype T-cell clones using immunohistochemistry after Vb identification by spectratyping. 32 Interestingly, our strategy appears easier to perform and allows the simultaneous analysis of a larger set of markers. In our series, we thus determined that the T-cell clone belonged to the CD4 þ subset or was double negative, but never CD8 þ . We also established that immunophenotypic aberrations may only partially involve the clonal population, as observed in 4 out of 11 cases showing a CD4 þ CD7À or CD4ÀCD10 þ phenotype. Such a result is not in favor of the hypothesis that peripheral T-cell lymphomas would arise from the expansion of a CD7À normal counterpart that underwent oncogenic transformation. It may rather reflect 'phenotypic plasticity'. Progressive downregulation of membrane protein expression has been described in Sezary's syndrome, 33, 34 and may play a role in the progression of T-cell lymphoma. 35 Intraclonal heterogeneity is indeed a well-known phenomenon illustrated on karyotypic studies demonstrating variable additional genetic abnormalities within a single clone. (Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer.) These results outline that TCR-Vb repertoire analysis is a more precise approach to identify and characterize a T-cell clone than abnormal expression of T-cell markers. Such an observation is of great importance when aiming at differentiating malignant T cells from normal resident subsets.
Moreover, characterization of a malignant clone by its Vb specificity is also a promising approach for disease monitoring. Indeed, a single tube including the appropriate Vb can be used to assess tumor burden and treatment response in diverse sites such as blood, bone marrow or needle aspirates. 36 Aberrant expression of T-cell markers by malignant T cells further allows for improved gating for Vb clonality analysis, leading to increase detection sensitivity and specificity. 12, 37 In this series of 30 peripheral T-cell lymphomas, a wide variety of Vb families was involved (14 out of 25 specific and 5 out of panel families). They were observed at low frequencies, except Vb17 that appeared to be expanded in 5/30 cases (Figure 3) . Of note, all five Vb17 peripheral T-cell lymphomas were classified as angioimmunoblastic T-cell lymphoma. Moreover, the EBV-infected case (patient 31) also demonstrated a high Vb17 expansion.
Considering the known association between EBV and angioimmunoblastic T-cell lymphoma, 37 its role as a common antigen or superantigen in the pathogenesis of this peripheral T-cell lymphoma subtype could be hypothesized. In addition, preferential use of some Vb families has been reported in leukemic phase of cutaneous T-cell lymphoma 16 and T-CD4 þ large granular lymphocytic proliferations in which the clone specificity for hCMV peptides has been demonstrated. 11, 39 By contrast, Lima et al 11 reported that CD8 þ T-cell large granular lymphocytic proliferations in blood samples showed a pattern of Vb distribution that mimics the frequency at which individual Vb families are represented in normal CD8 þ T cells, suggesting that CD8 þ T-cell large granular lymphocytic leukemia cells were clonally transformed in a random manner. Overall, there is some evidence to encourage further evaluation of the TCR-Vb profile in a larger number of peripheral T-cell lymphoma cases. In summary, TCR-Vb repertoire analysis in biopsy samples proved to be a highly specific and sensitive technique for peripheral T-cell lymphoma diagnosis when combined with conventional approaches. Once the Vb family involved has been identified, it may also prove a promising tool for the assessment of bone marrow involvement, and for follow-up evaluation in blood or needle aspirates. Most interestingly, the precise identification of the T-cell clone allows accurate evaluation of its size and immunophenotype.
